Pasithea Therapeutics Corp (KTTA)

$7.15 0.00 (0.00%)

14:50 EDT KTTA Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 26, 2024

Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 702

Day's Range $7.15 - $7.15

52-Week Range $0.26 - $9.25

Dividend & Yield N/A (N/A)

KTTA Stock Predictions, Articles, and Pasithea Therapeutics Corp News

From InvestorPlace
From the Web

Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?

By William White, InvestorPlace Writer Dec 11, 2023

Pasithea Therapeutics stock is climbing higher with heavy trading of KTTA shares alongside results from two preclinical trials.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Nov 30, 2023

It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 6, 2023

It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning!

KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today

By William White, InvestorPlace Writer Dec 23, 2021

Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Dec 23, 2021

Good morning, trader! Christmas is almost here but were aren't slowing down as we dive into the biggest pre-market stock movers for Thursday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Dec 2, 2021

Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 24, 2021

We're starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday!

KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today

By William White, InvestorPlace Writer Nov 23, 2021

Pasithea Therapeutics (KTTA) stock is rocketing higher on Tuesday after adding esketamine nasal spray to its U.K. offerings.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Nov 18, 2021

Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Oct 28, 2021

Good morning, investor! We're kicking off Thursday with a dive into the biggest pre-market stock movers traders will want to watch today!

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study (NASDAQ:KTTA)

From Seeking Alpha Jan 2, 2024

Pasithea Therapeutics (KTTA) has conducted a 1-for-20 reverse stock split and received FDA clearance for Phase 1 study of its oncology drug PAS-004. Read more here.

Pasithea stock soars as high as 190% on preclinical data (NASDAQ:KTTA)

From Seeking Alpha Dec 11, 2023

Pasithea (KTTA) shares soared as high as 190% after the company released encouraging data from two preclinical studies of its oncology drug candidate PAS-004. Read more here.

Pasithea stock jumps 12% on update for anti-tumor drug PAS-004 (KTTA)

From Seeking Alpha Nov 29, 2023

Pasithea (KTTA) stock jumped 12% on news that the company hopes to begin clinical testing of its drug PAS-004 in Q1 2024, pending FDA acceptance of its IND. Read more here.

Lucy Scientific makes bid to buy Pasithea for $0.85 in cash and stock (NASDAQ:LSDI)

From Seeking Alpha Jun 5, 2023

Lucy Scientific Discovery (LSDI), a producer of medicinal psychedelic compounds, has made a bid to acquire Pasithea Therapeutics (KTTA) for $0.85 per share in cash and stock.

Stocks That Hit 52-Week Lows On Tuesday

From Benzinga May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution

From Benzinga Apr 25, 2022

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Pasithea Therapeutics Corp (KTTA)

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Pasithea Therapeutics Corp (KTTA)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

KTTA Stock Predictions, Articles, and Pasithea Therapeutics Corp News

Subscriber Sign in